clinical trial · NCT05432596
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
Atopic DermatitisATI-1777 2.0% w/wATI-1777 1.0% w/wATI-1777 0.5% w/wVehicle
brief summary
This is a Phase 2b study to determine the safety, tolerability, pharmacokinetic (PK), and efficacy of ATI-1777 in patients 12 to 65 years old with mild to severe Atopic Dermatitis. Eligible participants will apply either ATI-1777 or Vehicle Topical Solution once daily or twice daily for 4 weeks.
started
May 11, 2022
primary completion
Oct 26, 2023
completion
Nov 14, 2023
last updated
Oct 26, 2024
official title
A Phase 2b, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis (AD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol